PMC5766393

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

There was no significant difference in infection rates during induction or post-induction therapy between Hispanic and non-Hispanic children treated for ALL on DFCI 05-001.

Effect: null; Induction: 25% vs 29%, p=0.36; Post-induction: 31% vs 32%, p=0.92

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15

The TCN2 rs1801198 polymorphism, which was more prevalent in Hispanic patients, was associated with inferior event-free survival within the Hispanic patient cohort in multivariable modeling, and was a

Effect: decline; HR=3.15